Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02919449 · ClinicalTrials.gov registry record · Phase 1
Dose Escalation Trial of Intra-Tumoral Injection of NIS Measles Virus in Combination With Atezolizumab
A Phase 1 study, sponsored by Vyriad.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT02919449: Clinical Trial Phase 1 study, sponsored by Vyriad.
NCT02919449 is a Phase 1 study that was terminated before completion, run by Vyriad. The registered enrollment target is 2 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02919449, a Phase 1 study, was terminated before completion, sponsored by Vyriad.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
This a Phase 1 study designed to determine the maximum tolerated dose (MTD) and toxicity of attenuated Measles virus (MV-NIS) combined with Atezolizumab in patients with recurrent and metastatic NSCLC.
Primary Outcome
To determine the maximum tolerated dose (MTD) of the intra-tumoral administration of an Edmonston strain MV genetically engineered to produce NIS (MV-NIS), in combination with the PD-L1 inhibitor atezolizumab
Interventions
- BIOLOGICAL Atezolizumab
- BIOLOGICAL MV-NIS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2017-08-03 |
| Est. Completion | 2018-01-19 |
| Phase | Phase 1 |
Why NCT02919449 stopped before completion
NCT02919449 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 2 interventions - of which Atezolizumab is the first listed.
NCT02919449 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02919449 about?
NCT02919449 is a clinical study titled "Dose Escalation Trial of Intra-Tumoral Injection of NIS Measles Virus in Combination With Atezolizumab". This a Phase 1 study designed to determine the maximum tolerated dose (MTD) and toxicity of attenuated Measles virus (MV-NIS) combined with Atezolizumab in patients with recurrent and metastatic NSCLC.
What is the current status of trial NCT02919449?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2017-08-03. Estimated completion is 2018-01-19.
What interventions are being tested in trial NCT02919449?
The interventions under investigation include: Atezolizumab (BIOLOGICAL), MV-NIS (BIOLOGICAL).
Who is sponsoring clinical trial NCT02919449?
This trial is sponsored by Vyriad, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02919449's enrollment target sits among peer trials
2 2000th of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI